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166REPLY: Cisplatin-Associated AorticThrombosis: A Review of Cases Reported to
the FDA Adverse Event Reporting SystemWe are grateful to Dr. Nguyen and colleagues for their
interest in our recent study (1), published in JACC:
CardioOncology, that assessed the vascular effects of
cisplatin-based chemotherapy in patients with
testicular cancer. We read with interest their work
that highlights 37 cases of aortic thrombosis
associated with cisplatin in the U.S. Food and Drug
Administration (FDA) Adverse Event Reporting
System and in medical publications. Their data are
important in further demonstrating the potential for
these clinically serious adverse thrombotic effects
of cisplatin-based chemotherapy. In that study,
of the 37 patients studied, aortic thrombosis was
associated with a serious clinical outcome in all
patients, with 1 patient requiring limb amputation.
There were also 4 deaths. The total number of
patients treated with cisplatin during the period
studied is not available from this adverse event
reporting system. However, the data clearly
highlight that the beneficial anticancer effects of
cisplatin-based chemotherapy (2,3) can come at the
cost of an increased risk of serious and potentially
fatal adverse cardiovascular effects.
It is vital that we continue to improve our under-
standing of the mechanisms underlying this arterial
prothrombotic effect of cisplatin. Our own studies
demonstrated that acute endothelial dysfunction may
be implicated, with a marked endothelial toxic effect
in the immediate periexposure period (1). Controlled
trials of preventive therapies are lacking and should
examine the effects of antithrombotic agents,
antiplatelet drugs, or statins. Prospective risk
stratification is also a challenge, but close attention
should be paid to those patients with pre-existing
cardiovascular risk factors. Cigarette smoking was
common in patients with aortic thrombus, and this
is strongly associated with endothelial dysfunctionand impaired endogenous fibrinolysis (4). The
combination of cigarette smoking and cisplatin
exposure may be particularly potent in the
propensity for thrombogenesis and propagation. We
must ensure that the impressive anticancer effects
of cisplatin do not come at a potentially
unacceptable cardiovascular cost. A collaborative
approach among cardiologists, oncologists, and
primary care physicians should be encouraged.Alan C. Cameron, MBChB, PhD
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